

EXPLORE A KEY SUSPECT IN ATOPIC DERMATITIS

The LEO Pharma logo is a registered trademark of LEO Pharma A/S.

© 2019 LEO Pharma Inc. All rights reserved. 09/19 MAT-20101a

UNCOVER IT NOW >>



Healio > News > Dermatology > Cutaneous Oncology

American Society for Dermatologic Surgery

Healio
Psoriatic Disease

By [Rebecca L. Forand](#)

Source/Disclosures

Source: Hamel R, et al. Impact of COVID-19 on a Midwestern academic dermatologic surgery practice. Presented at: American Society for Dermatologic Surgery annual meeting; Oct 9-11, 2020 (virtual meeting).

Disclosures: Hamel reports no relevant financial disclosures.

October 26, 2020 | 1 min read

SAVE

Fewer basal cell carcinomas treated following COVID-19

✓ ADDED TO EMAIL ALERTS

Fewer basal cell carcinomas were treated after the declaration of the COVID-19 pandemic, with those being treated having a higher histopathological upgrade rate, according to a study.

A retrospective chart review presented at the American Society for Dermatologic Surgery annual meeting compared the number of patients at Washington University in St. Louis [undergoing Mohs surgery](#) before and after the WHO's COVID-19 pandemic declaration.

The study also compared stages, time from initial biopsy to surgery, histology of the tumors and incidence of upgrading, [Remi Hamel, MD](#), said.

The CMS recommended delaying elective or nonessential surgeries after the pandemic declaration.


In-person visits in the 60 days before the pandemic declaration totaled 800, while only 338 occurred in the 60 days after the declaration.

The total number of tumors treated in the first time period was 372 compared with 231 in the second time period. In addition, the histopathological upgrade rate was 10.82% during the second period compared with 6.18% in the first period.

“There was a relative decrease in the number of [basal cell carcinomas](#) treated in period two,” Hamel said. “And those that were treated had a higher histopathological upgrade rate, reflecting prioritization of the highest-risk tumors during the pandemic.”

basal cell carcinomas

covid-19



UNCOVER IT NOW >>

The LEO Pharma logo is a registered trademark of LEO Pharma A/S.

© 2019 LEO Pharma Inc. All rights reserved. 09/19 MAT-20101c

READ NEXT

Cutaneous sebaceous carcinomas did not recur after Mohs surgery

✓ ADDED TO EMAIL ALERTS


American Society for Dermatologic Surgery

MORE FROM THIS MEETING

Related Content



Oncology Overdrive



COVID-19 Resource Center

Covid-19: Reward healthcare staff for pandemic work, says BMA [↗](#)

Abi Rimmer, The BMJ

Covid-19: Cancer Research urges mass testing to enable care to continue during pandemic [↗](#)

Elisabeth Mahase, The BMJ, 2020

IMPACT-Restart: the influence of COVID-19 on postoperative mortality and risk factors associated with SARS-CoV-2 infection after orthopaedic and trauma surgery [↗](#)

Nicholas D. Clement et al., The Bone & Joint Journal

30-day mortality following trauma and orthopaedic surgery during the peak of the COVID-19 pandemic [↗](#)

Paul N. Karayiannis et al., Bone & Joint Research, 2020

Powered by **TREND MD**

Follow Healio [t](#) [f](#) [in](#) [📡](#)

Tell us what you think about Healio.com >

Help

Sign Up for Email

Get the latest news and education delivered to your inbox

Email address

Specialty

All Specialties ▼

SUBSCRIBE

Account Information

My Saved

Log Out

Update Publication Mailing Address

Subscribe

My Account

Email Subscriptions and Alerts

Institutional and Library Subscriptions

Help

Healio.com

About Healio

Feedback

Healio Network

Publications

Contact the News Desk

Contact Us

About the Wyanoke Group

Healio Jobs [↗](#)

Advertising Information

Reprints

Sitemap

Legal

Medical Disclaimer

Privacy Policy

Do Not Sell My Personal Information

Editorial Policy and Philosophy

Terms and Conditions

Permissions

©2020 Healio All Rights Reserved.